Drug Information

Drug (ID: DG01842) and It's Reported Resistant Information

Name	YK-4-279
Synonyms	YK-4-279; 1037184-44-3; YK 4-279; 4,7-dichloro-3-hydroxy-3-(2-(4-methoxyphenyl)-2-oxoethyl)indolin-2-one; 4,7-dichloro-3-hydroxy-3-[2-(4-methoxyphenyl)-2-oxoethyl]-1H-indol-2-one; CHEMBL2011500; 4,7-Dichloro-1,3-dihydro-3-hydroxy-3-[2-(4-methoxyphenyl)-2-oxoethyl]-2H-indol-2-one; C17H13Cl2NO4; 4,7-dichloro-1,3-dihydro-3-hydroxy-3-[2-(4-methoxyphenyl)-2-oxoethyl]-2H-indole-2-one; MLS006010813; SCHEMBL3486735; CHEBI:94301; DTXSID80660065; EX-A524; HMS3741G19; AOB87740; BCP13213; BDBM50379275; MFCD18382120; NSC765436; s7679; AKOS024457962; CCG-268236; CS-0667; NSC-765436; YK4-279; NCGC00346886-01; NCGC00346886-04; NCGC00346886-09; AC-33063; AS-17053; HY-14507; QC-11745; SMR004701745; FT-0753857; Y0289; F51067; BRD-A62182663-001-02-2; Q27166120; 4,7-dichloro-3-hydroxy-3-(2-(4-methoxyphenyl)-2-oxoethyl)indolin-2-one(YK-4-279) Click to Show/Hide
Structure
Drug Resistance Disease(s)	Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases) Ewing sarcoma [ICD-11: 2B52] [1]
Target	.	NOUNIPROTAC	[1]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
Formula	4
IsoSMILES	COC1=CC=C(C=C1)C(=O)CC2(C3=C(C=CC(=C3NC2=O)Cl)Cl)O
InChI	InChI=1S/C17H13Cl2NO4/c1-24-10-4-2-9(3-5-10)13(21)8-17(23)14-11(18)6-7-12(19)15(14)20-16(17)22/h2-7,23H,8H2,1H3,(H,20,22)
InChIKey	HLXSCTYHLQHQDJ-UHFFFAOYSA-N
PubChem CID	44632017

Type(s) of Resistant Mechanism of This Drug

EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Click to Show/Hide the Resistance Disease of This Class

Ewing sarcoma [ICD-11: 2B52]

Click to Show/Hide

Drug Resistance Data Categorized by Their Corresponding Mechanisms
Epigenetic Alteration of DNA, RNA or Protein (EADR)			Click to Show/Hide
Key Molecule: Hepatocellular carcinoma up-regulated long non-coding RNA (HULC)				[1]
Molecule Alteration	Up-regulation		Interaction	Molecule Info
Resistant Disease	Ewing sarcoma [ICD-11: 2B52.0]			Disease Info
Experimental Note	Revealed Based on the Cell Line Data
In Vitro Model	LAP-35 cells	Bone marrow	Homo sapiens (Human)	CVCL_A096
Experiment for Molecule Alteration	RNA-seq assay
Experiment for Drug Resistance	MTS assay
Mechanism Description	Ewing sarcomas (ES) characterized by in frame chromosomal translocations giving rise to chimeric transcription factors, such as EWS-FLI1. High levels of HULC correlate with ES aggressiveness, whereas HULC depletion reduces ES cell growth.

References

Ref 1	Small molecule inhibition of Ewing sarcoma cell growth via targeting the long non coding RNA HULCCancer Lett. 2020 Jan 28;469:111-123. doi: 10.1016/j.canlet.2019.10.026. Epub 2019 Oct 19.